Publicaties
Genotypic and phenotypic heterogeneity among Mycobacterium tuberculosis isolates from pulmonary tuberculosis patients Instituut voor Tropische Geneeskunde
Evaluation of the gen-probe amplified Mycobacterium tuberculosis direct test for the routine diagnosis of pulmonary tuberculosis Instituut voor Tropische Geneeskunde
Usefulness of Mycobacterium tuberculosis molecular typing in a tuberculosis low-endemic agro-industrial setting of Brazil Instituut voor Tropische Geneeskunde
Mycobacterium tuberculosis strains of Beijing genotype are rarely observed in tuberculosis patients in South America Instituut voor Tropische Geneeskunde
Assessment of population structure and major circulating phylogeographical clades of Mycobacterium tuberculosis complex in Bangladesh suggests a high prevalence of a specific subclade of ancient M. tuberculosis genotypes Instituut voor Tropische Geneeskunde
Analysis of the population structure of Mycobacterium tuberculosis in Ethiopia, Tunisia and The Netherlands; usefulness of DNA typing for global tuberculosis epidemiology Instituut voor Tropische Geneeskunde
Detection of tuberculosis drug resistance: a comparison by Mycobacterium tuberculosis MLPA assay versus Genotype®MTBDRplus Instituut voor Tropische Geneeskunde
BACKGROUND: To cope with the emergence of multidrug-resistant tuberculosis (MDR-TB), new molecular methods that can routinely be used to screen for a wide range of drug resistance related genetic markers in the Mycobacterium tuberculosis genome are urgently needed.
OBJECTIVE: To evaluate the performance of multiplex ligaton-dependent probe amplification (MLPA) against Genotype® MTBDRplus to detect resistance to isoniazid (INHr) and ...
Survival of Mycobacterium tuberculosis and Mycobacterium bovis BCG in lysosomes in vivo KU Leuven
Half of rifampicin-resistant Mycobacterium tuberculosis complex isolated from tuberculosis patients in Sub-Saharan Africa have concomitant resistance to pyrazinamide Instituut voor Tropische Geneeskunde Universiteit Antwerpen
Background
Besides inclusion in 1st line regimens against tuberculosis (TB), pyrazinamide (PZA) is used in 2nd line anti-TB regimens, including in the short regimen for multidrug-resistant TB (MDR-TB) patients. Guidelines and expert opinions are contradictory about inclusion of PZA in case of resistance. Moreover, drug susceptibility testing (DST) for PZA is not often applied in routine testing, and the prevalence of resistance is ...